Core Viewpoint - The article discusses a significant advancement in the field of neuroscience, specifically the successful creation of human sympathetic ganglia organoids (hSGO) from human pluripotent stem cells (hPSC), which can be integrated with human heart organoids (hHFO) to form a human sympathetically innervated heart organoid (hSHO) [1][6]. Group 1: Research Background - The sympathetic ganglia are a crucial component of the peripheral nervous system (PNS) and play an essential role in maintaining homeostasis [4]. - Previous attempts to create organoids representing the peripheral nervous system have been limited, particularly in mimicking the self-organizing development of sympathetic ganglia [5]. Group 2: Research Methodology - The research team utilized directed 3D differentiation techniques from human pluripotent stem cells to develop a method for generating human sympathetic ganglia organoids (hSGO), which exhibit directed and self-organizing sympathetic neuronal differentiation [5]. - The hSGO produced sympathetic neurons and glial cells, demonstrating functional development over long-term culture [5]. Group 3: Key Findings - By fusing hSGO with hHFO, the researchers successfully recreated the functional sympathetic innervation of the human heart, resulting in the formation of hSHO [6]. - The hSHO model allows for the evaluation of factors regulating sympathetic innervation of the heart, such as nerve growth factor signaling, and reveals that inter-tissue interactions influence the development of both sympathetic nerves and the heart [6].

智通财经APP讯，康哲药业(00867)发布公告，1类新药注射用Y-3(拟定中文通用名：注射用洛贝米柳)(注 射用Y-3或"产品")新药上市许可申请(NDA)已于2025年12月11日获得中国国家药品监督管理局(NMPA)受 理。产品为一种拟用于急性缺血性卒中的脑细胞保护剂。 根据国家卫健委发布的《脑血管病防治指南(2024年版)》，我国每年新发卒中约394万例，占全球新发 病例三分之一，其中缺血性卒中占比约72%，年新发病例超280万;现患病的卒中患者已超2800万人。 2021年中国死因监测数据显示，卒中死亡占全国总死亡人数的23%。过去三十年，我国卒中相关残疾的 疾病负担持续加重，叠加人口老龄化加快等因素，未来卒中防控压力将进一步增大，给患者家庭和社会 带来巨大挑战。此外，卒中后抑郁和焦虑是卒中常见并发症，发病率分别达到约30%和25%，会影响患 者神经功能恢复，甚至增加死亡风险，严重影响患者预后。注射用Y-3对广大卒中患者长期神经功能改 善和总体预后具有重大潜在价值，市场前景广阔。 于2023年8月24日，本集团通过本公司全资附属公司与一家以临床需求为导向、创新与研发驱动的新药 企业南京宁丹新药技术股 ...